Overview

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Nave Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-30

Target enrollment:

Participant gender:

Summary

This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.

Phase:

PHASE2

Details

Lead Sponsor:

TuHURA Biosciences, Inc.

Treatments:

pembrolizumab